Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA Xsail (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Avanir Pharmaceuticals; Currax Pharmaceuticals
- 06 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2021 Planned End Date changed from 31 Dec 2021 to 31 Aug 2023.